Quagen Pharmaceuticals

Quagen Pharma is a private, commercial-stage generic drug manufacturer with a fully integrated model encompassing development, regulatory submission, and manufacturing. The company operates from a 170,000 sq. ft. state-of-the-art facility and has demonstrated aggressive regulatory activity, submitting numerous Abbreviated New Drug Applications (ANDAs) to the FDA. Led by a seasoned management team with deep industry experience, Quagen targets a diverse product pipeline in oncology and other therapeutic areas, leveraging its capabilities in complex dosage forms like transdermal patches and controlled substances to compete in the generic market.

Integrated generic pharmaceutical development and manufacturing platform for complex dosage forms including oral solids (modified release), liquids, semisolids, suppositories, and transdermal patches, with specialized capabilities for Schedule I-V controlled substances.

Quagen competes with large, diversified generic manufacturers (e.g., Teva, Mylan, Sandoz) and smaller specialty generics firms. Its differentiation lies in its broad in-house capabilities for complex dosage forms like transdermals and suppositories, and its focus on controlled substances, which are higher-barrier segments within the generic market.